Alert detail
FDA Approval: NDA 219617 — Type 5 - New Formulation or New Manufacturer
What changed
IV trabectedin new formulation lands in Part B; verify J-code mapping.
Who’s affected: Oncology billing teams · Effective: October 1, 2026
Affected codes
CodesJ9393
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 1 billing code.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.